Effect of vascular disrupting therapy by lipid nanoparticles on the tumor microenvironment
- 16 May 2026
- journal article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 699, 126988
Abstract
No abstract availableKeywords
Funding Information
- Japan Agency for Medical Research and Development (JP21ak0101172)
- Japan Society for the Promotion of Science (23H05451)
- Japan Society for the Promotion of Science (24H00785)
- Japan Society for the Promotion of Science (22K19448)
This publication has 25 references indexed in Scilit:
- Selective vascular disrupting therapy by lipid nanoparticle-mediated Fas ligand silencing and stimulation of STINGBiomaterials, 2025
- Interval- and cycle-dependent combined effect of STING agonist loaded lipid nanoparticles and a PD-1 antibodyInternational Journal of Pharmaceutics, 2022
- Combined nano cancer immunotherapy based on immune status in a tumor microenvironmentJournal of Controlled Release, 2022
- Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal MalignanciesDrug Safety, 2019
- A lipid nanoparticle for the efficient delivery of siRNA to dendritic cellsJournal of Controlled Release, 2016
- RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA systemJournal of Controlled Release, 2014
- Mechanisms of resistance to anti-angiogenesis therapiesBiochimie, 2013
- A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivoJournal of Controlled Release, 2012
- Cellular abnormalities of blood vessels as targets in cancerCurrent Opinion in Genetics & Development, 2005
- Acquired resistance to EGFR inhibitors: mechanisms and prevention strategiesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004